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Visual perception in Parkinson disease
dementia and dementia with Lewy bodies
U.P. Mosimann, MD; G. Mather, PhD; K.A. Wesnes, PhD; J.T. O’Brien, DM; D.J. Burn, MD;
and I.G. McKeith, MD
Abstract—Objective: To quantify visual discrimination, space-motion, and object-form perception in patients with Parkin-
son disease dementia (PDD), dementia with Lewy bodies (DLB), and Alzheimer disease (AD). Methods: The authors used
a cross-sectional study to compare three demented groups matched for overall dementia severity (PDD: n  24; DLB: n 
20; AD: n  23) and two age-, sex-, and education-matched control groups (PD: n  24, normal controls [NC]: n  25).
Results: Visual perception was globally more impaired in PDD than in nondemented controls (NC, PD), but was not
different from DLB. Compared to AD, PDD patients tended to perform worse in all perceptual scores. Visual perception of
patients with PDD/DLB and visual hallucinations was significantly worse than in patients without hallucinations.
Conclusions: Parkinson disease dementia (PDD) is associated with profound visuoperceptual impairments similar to
dementia with Lewy bodies (DLB) but different from Alzheimer disease. These findings are consistent with previous
neuroimaging studies reporting hypoactivity in cortical areas involved in visual processing in PDD and DLB.
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Parkinson disease (PD) is associated with a higher
risk of developing dementia compared to healthy el-
derly controls; longitudinal studies suggest that up
to 78% of PD patients will develop dementia after
nearly two decades of motor symptoms.1 Once de-
mentia is established, clinical symptoms of PD de-
mentia (PDD) may show, apart from a longer
duration of motor features, considerable overlap with
dementia with Lewy bodies (DLB). The postural
instability-gait type of parkinsonism is over-
represented in PDD and DLB2 and both disorders
show similar fluctuation of attention3 and response
to cholinergic therapy.4,5
Studies comparing visual perception and visual
construction of PDD with Alzheimer disease (AD)
have revealed contradictory results. Some studies re-
port PDD to be more impaired,6,7 whereas other stud-
ies found no differences.8,9 Similar inconsistencies
have been found when perception of PD patients was
compared with healthy controls.10 Since operational-
ized criteria to define the clinical boundaries be-
tween PD and PDD or PDD and DLB require
refinement, these inconsistencies may be partly due
to diagnostic heterogeneity. When DLB was com-
pared with AD, studies consistently reported greater
visual impairment in DLB11 and a recent study
found similar impairments in pentagon copying in
DLB and PDD.12 Some of these studies used con-
struction tasks as evidence, but this may not be le-
gitimate given the motor impairments in these
patients. Studies quantifying visual perception of
DLB and PDD using tasks without motor require-
ments are lacking.
Peripheral structures such as the retina, the optic
nerve and tract, and primary visual cortex are mul-
timodal in their function, whereas the visual associ-
ation cortex is more specialized.13 Low-level visual
discrimination is mainly processed in visual area V1/
V2, whereas high-level visual functions require addi-
tional activation of large extrastriatal cortical
networks.14 Two visual pathways can be distin-
guished: the ventral occipito-temporal pathway,
which is required for detailed analysis and identifi-
cation of objects and forms, and the dorsal occipito-
parietal pathway, required for spatial vision and
motion perception.14 Task selection of the present
study took these theoretical considerations into ac-
count. We aimed to quantify perceptual differences
in PDD, DLB, and AD patients matched for overall
dementia severity, and in non-demented controls
(PD and NC). We tested visual discrimination,
object-form perception, and space-motion perception
to assess impairments in different visual cortical
pathways. Since PDD and DLB have combined motor
Additional material related to this article can be found on the Neurology
Web site. Go to www.neurology.org and scroll down the Table of Con-
tents for the December 14 issue to find the title link for this article.
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and visuoperceptual impairments, all tasks used in
the present study did not require motor responses
and were not time driven. Based on previous neuro-
imaging findings,15,16 we hypothesized similar visual
impairments in PDD and DLB and expected impair-
ments to exceed those of matched AD patients.
Methods. Subjects. All subjects were recruited from the New-
castle MRC prospective outpatient cohort.2 Characteristics of the
sample are summarized in table 1. The UK PD Society Brain
Bank Clinical Diagnostic Criteria17 were used to make the diagno-
sis of PD, the National Institute of Neurologic and Communicative
Disorders and Stroke and AD and Related Disorders Association
(NINCDS-ADRDA)18 for AD, and the DLB Consensus guidelines
for DLB,19 following the recommendation that patients with par-
kinsonian features preceding cognitive impairment for more than
12 months should be diagnosed with PDD.19 PDD patients had to
have PD for more than 12 months before developing dementia.19
Patients were required to have a caregiver providing regular care
and support and to score at least 10 on the Mini-Mental State
Examination (MMSE).20 Subjects with coexisting medical illness
or a history of visual impairment due to cataract, glaucoma, or
macular degeneration were excluded. The only antiparkinsonian
medication allowed was levodopa. Patients stabilized on cholines-
terase inhibitors (ChE-I) were eligible for the study provided they
were on a stable dose for more than 3 months. The percentage of
demented patients on long-term ChE-I was not different between
the diagnostic groups (PDD: 58%, DLB: 65%, and AD: 69%). All
patients with PDD were treated with levodopa, but only 43% of
DLB were on dopaminergic treatment. Of 146 subjects invited,
118 gave written informed consent; 2 patients had to be excluded
because they did not understand the task instructions. The local
research ethics committee granted ethical approval.
Procedure. Global cognitive impairment was assessed with
the Cambridge Cognitive Examination (CAMCOG)21 and for the
purpose of this study, tests assessing apraxia were analyzed sepa-
rately from tests measuring visuoconstructional ability, i.e.,
praxis and construction scores. CAMCOG visual construction in-
cluded spiral, pentagon, three-dimensional house and clock copy-
ing. Parkinsonism in DLB was defined as bradykinesia, plus one
or more of rest tremor, muscular rigidity, and postural instability
without other explanation. Severity of extrapyramidal features
was assessed with the Unified PD Rating Scale (UPDRS) motor
score (part III).22 A cutoff score of more than 6 in the one-day
fluctuation assessment scale defined fluctuation.23 The Neuropsy-
chiatric Inventory (NPI)24 was used to determine whether a sub-
ject was experiencing recurrent visual hallucinations during the
month previous to the assessment. Analyzing questions 2 or 3 in
the hallucination section of the NPI identified recurrent visual
hallucinations. In patients with recurrent visual hallucinations,
the caregiver agreed with either of these questions and reported a
frequency and severity of at least one. The Bristol Activities of
Daily Living Scale (Bristol ADL)25 was used to assess impairments
in activities of daily living. The neuro-ophthalmologic assessment
included external inspection of the eyes, assessment of pupil reac-
tions, light reflex (penlight), measurement of near vision (Landolt
broken rings, test distance 40 cm), assessment of ocular move-
ments, and estimation of the visual field by confrontation test.
The red reflex and ocular fundus were assessed with direct
ophthalmoscopy.
Assessment of visual perception. Visuoperceptual tasks were
presented in a multiple-choice format on a 14-inch computer
screen in a standardized, darkened environment. Subjects sat 40
cm in front of the computer screen. Tasks were not time driven,
subjects responded verbally, and the examiner handled all but-
tons. The instruction of each task was read while an example was
presented on the screen. Once the correct answer was given, the
task started and no further feedback was given. Different random
arrangements of stimulus presentation were used in each task.
The assessment lasted about 30 to 45 minutes. Figure E-1 on the
Neurology Web site (www.neurology.org) gives an overview of all
tasks used.
Visual discrimination. Length and size discrimination tasks.
Pairs of lines/circles were presented side-by-side on the screen and
subjects had to decide which of the lines/circles, left or right, were
longer/larger. The stimulus field dimensions were 140 mm wide
and 150 mm tall. Reference stimulus (70 mm) and comparison
Table 1 Demographics and clinical description of the sample
NC, n  25 PD, n  24 PDD, n  24 DLB, n  20 AD, n  23
Between-group
comparison
Age, y 75.5  5.9 76.9  5.4 75.2  6.2 77.6  6.9 77.8  6.8 NS
Education, y 14.2  2.1 12.9  1.8 13.6  1.6 13.7  1.9 13.4  1.0 NS
Female, % 44 21 25 45 48 NS
Estimated dementia onset, y NA NA 4.0  1.9 3.2  2.1 5.4  1.7 p  0.001*
MMSE (max. 30) 29.0  1.3 28.1  1.4 20.8  3.8 19.4  5.2 20.0  5.4 p  0.0001†
Estimated onset parkinsonism, y NA 6.3  5.1 8.3  5.0 2.8  1.7 NA NS
UPDRS motor score (max. 108) 1.6  1.8 29.8  11.1 37.8  12.7 29.2  17.3 6.7  6.5 p  0.0001‡
NPI (max. 144) 0.0  0.2 3.9  5.1 17.8  14.5 15.5  12.0 11.0  11.8 p  0.0001†
Fluctuation (max. 21) 0.0  0.0 1.3  2.2 6.0  4.2 4.8  4.0 2.0  2.9 p  0.0001§
Bristol-ADL (max. 60) 0.0  0.0 3.1  5.7 19.4  10.9 21.7  11.2 13.1  10.1 p  0.0001¶
Values are mean  SD.
Post-hoc Bonferroni tests compared NC vs PD, PDD vs PD, PDD vs DLB, PDD vs AD, and DLB vs AD, and significant group differ-
ences are reported.
* PDD vs AD: p  0.047; DLB vs AD: p  0.001.
† PDD vs PD  0.0001.
‡ PD vs NC  0.0001; PDD vs AD: p  0.0001; DLB vs AD: p  0.0001.
§ PDD vs PD  0.0001; PDD vs AD: p  0.001; DLB vs AD: p  0.027.
¶ PDD vs PD  0.0001; DLB vs AD: p  0.026.
NC  normal controls; PD  non-demented Parkinson disease; PDD  Parkinson disease dementia; DLB  Dementia with Lewy bod-
ies; AD  Alzheimer disease; NS  not significant (p  0.05); MMSE  Mini-Mental State Examination; UPDRS  Unified Parkinson
Disease Rating Scale; NPI  Neuropsychiatric Inventory; Fluctuation  One Day Fluctuation Assessment Scale; Bristol-ADL  Bristol
Activities of Daily Living scale.
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stimulus were separated by 70 mm and the position of the longer
line/larger circle varied randomly. To eliminate cues based on the
absolute position of the stimulus features such as end-lines, the
position of each stimulus was randomly jittered from trial to trial
with a diameter of 7 mm. The test used an adaptive psychophysi-
cal procedure to find the stimulus difference required for a subject
to achieve reliable discrimination. Each correct response led to a
decrease in the stimulus difference for the next trial (by 1 mm),
and each incorrect response led to an increase in the difference for
the next trial (by 3 mm). As a result, the test converged on an
estimate of the threshold, expressed as difference of size or length
(in %), that the subject detected with 75% accuracy.26 Thirteen
trials were presented in each task.
Angle discrimination task. The task was a simplified version
of Benton’s task.27 Our task used 5 (instead of 11) standard lines
at 30 deg (instead of 18 deg) intervals, with subjects judging one
comparison line (instead of two) in each trial. The stimulus field
dimensions were 180 mm wide and 150 mm tall. Twenty trials
were presented. Subjects were required to match the angle of the
single line to one of five lines forming a semicircle.
Object and form perception. Overlapping figures task. This
overlapping figures task was described by De Renzi et al.28 In each
trial a series of four unique pictures of animals, utensils, clothing,
or fruits were presented on the screen and subjects decided which
of the four pictures was included in the simultaneously presented
overlapping figure. The stimulus field dimensions were 180 mm
wide and 150 mm tall. Thirteen trials were presented.
Form perception task. This task was based on the WAIS-R
block design subtest.29 Two boxes with slightly different forms
were presented side-by-side and the subject had to decide in which
quadrant the two boxes were different. Stimuli were not matched
systematically for mean luminance. Each box was 60 mm wide
and 60 mm tall, and the two boxes were separated by 20 mm.
Thirteen trials were presented.
Space and motion perception. Dot position task. This task is
based on the dot position task of Warrington and James.30 In each
trial, two squares were presented side-by-side, one containing a
dot and the other five different numbers at random position. The
position of the dot exactly matched the position of a number and
the subject was required to name this number. Each square was
70  70 mm and the squares were separated by 30 mm. Thirteen
trials were presented.
Motion perception task. The stimuli for this task were de-
signed to match those used in Vaina31 as closely as possible. In
each trial, two black squares (70  70 mm) were presented side by
side on the screen, separated by 30 mm. Each square contained 12
small (3 mm diameter) white dots in random positions, moving in
random directions and bouncing off the sides of the square. Within
a square all dots moved with the same velocity, but the dots
moved with different velocities in the two squares. Four velocities
were presented: 15 mm/second, 20 mm/second, 44.8 mm/second,
and 60 mm/second. The velocity ratios were the ratio of two differ-
ent velocities presented in a trial: 1.33  20/15; 2.24  44.8/20; 3
 60/20. When the ratio was 3, for example, all dots in one square
moved at three times faster than the dots in the other square. The
side on which each velocity appeared was selected randomly.
There were 12 trials—i.e., four presentations of each velocity ra-
tio—and subjects determined which of the two squares contained
the faster moving dots.
Visual counting task. This task is a modified version of the
visual counting task used by Fujimori et al.32 The stimulus in each
trial consisted of 10 to 12 colored shapes (white, green, blue,
triangles and squares). There were between 1 and 5 target stimuli
in each trial (average 3.5). In each of the 13 trials the subject
needed to count the number of shapes containing one of five pos-
sible attributes (e.g., how many squares). The stimulus field di-
mensions were 80  80 mm.
Data analysis. Outcome measures were errors (in percent) in
all tasks except the line and size discrimination tasks. Standard-
ized z-values were calculated to compare thresholds in the size/
length discrimination tasks and percentage of errors in the angle
discrimination task. The mean of the three z-values was the dis-
crimination score. To get a measure of the impairment in the
ventral visual pathway, mean errors of the overlapping figure and
form perception tasks were calculated (object-form perception
score). The mean errors in motion, dot position, and visual count-
ing tasks were a measure of the impairment in the dorsal visual
pathway (space-motion perception score). The Statistical Package
for Social Sciences (SPSS Version 11) was used for statistical
analysis. The distribution of the data was examined for normality
(Kolmogorov-Smirnov test). Provided the data did not deviate
from normal distribution, the five groups were compared with
parametric tests (i.e., one-way analysis of variance [ANOVA]) and
subsequently post hoc Bonferroni tests were used for two-group
comparisons. Means and SD were calculated to represent central
tendency and dispersion. Pearson-rank-correlation was used for
correlative analysis. All reported p values were two-tailed and a p
value of less than 0.05 was considered statistically significant.
Results. Demographic characteristics. The five groups
were well matched with respect to age, sex, and education
and the three dementia groups did not differ in global
cognitive impairment (see table 1). Compared to the AD
group, the DLB and PDD groups had higher UPDRS motor
scores, higher fluctuation scores, shorter dementia dura-
tion, and greater impairment in activities of daily living
(Bristol ADL). No differences in these scores were found
when DLB was compared with PDD. The frequencies of
the core clinical features—fluctuation of cognition (PDD
54%; DLB 35%; AD 8%), recurrent visual hallucinations
(PDD 75%; DLB 90%; AD 8%), and extrapyramidal fea-
tures (PDD 100%; DLB 85%; AD 13%)—were similar in the
DLB and PDD groups (chi square or Fisher’s exact t-test:
p  0.05; NS) but different from AD (Fisher’s exact t-test
for comparison PDD vs AD and DLB vs AD: p  0.05).
Visual acuity did not differ between groups (controls
0.40  0.16; PD 0.40  0.14; PDD 0.34  0.11; DLB 0.37 
0.18;AD0.420.17) (ANOVA:NS)andotherneuro-ophthal-
mologic assessments did not reveal impairments interfer-
ing with perceptual testing.
Table 2 summarizes CAMCOG data. One-way ANOVA
revealed significant group differences in all except the
praxis score. PD was similar to controls and different from
PDD in all but the CAMCOG abstract thinking score. In
abstract thinking PD were similar to PDD and more im-
paired than controls. Group comparison did not reveal any
differences between PDD and DLB. Compared to AD, PDD
and DLB patients were significantly less impaired in mem-
ory scores, but more impaired in the visual construction
scores, and the DLB group scored lower in the perception
score compared to AD. Visual construction CAMCOG
scores did not correlate with UPDRS-motor scores in PDD
group (Pearson correlation: r  0.190, p  0.05, NS) but
correlated in the DLB group (Pearson correlation: r 
0.612, p  0.007).
Visual perception. Results for discrimination, object-
form, and space-motion perception are summarized in the
figure, A through C. Visual discrimination scores (z-
values) were different between the groups (ANOVA: p 
0.0001) and DLB and PDD patients were more impaired
than AD (post-hoc Bonferroni tests: DLB vs AD: p  0.007;
PDD vs AD: p  0.051), but were not different from each
other (post-hoc Bonferroni tests PDD vs DLB: NS) (see
figure 1A). Between-group differences were also found in
object-form and space-motion perception (ANOVA: p 
0.0001). The impairment in object-form perception (see fig-
ure 1B) of PDD and DLB patients was greater compared
with AD patients (post-hoc Bonferroni tests: DLB vs AD:
p  0.003; PDD vs AD: p  0.001), but not different in
DLB and PDD patients (post-hoc Bonferroni tests PDD vs
DLB: NS). Space-motion perception (see figure 1C) re-
vealed a similar pattern of impairment in that the DLB
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group did not differ from PDD but tended to be more im-
paired compared to AD (post-hoc Bonferroni tests: DLB vs
AD: p  0.074). PD was similar to controls but less im-
paired than PDD in all scores (post-hoc Bonferroni tests for
all: p  0.0001). The PDD group made more errors in
object-form perception compared to space-motion percep-
tion (paired sample t-test: p  0.0001), a difference also
found in the DLB group (paired sample t-test: p  0.0001)
but not in the AD group (paired sample t-tests: NS). The
raw data of all tasks are summarized in table E-1 on the
Neurology Web site.
There were few patients without recurrent hallucina-
tions (RVH) in the DLB and PDD groups; therefore the
PDD and DLB groups were pooled to compare patients
with and without hallucinations. Results are shown in ta-
ble 3. Global cognitive impairment of patients with visual
hallucinations (MMSE) was not different from patients
without hallucinations and the two groups did not differ
with regard to education, frequency of extrapyramidal
symptoms, or fluctuation. Patients with RVH were signifi-
cantly more impaired in visual discrimination, space-
motion perception, and object-form perception compared to
patients without visual hallucinations.
Within each dementia group, patients on ChE-I did not
perform differently compared to patients not taking ChE-I
in visual discrimination, object-form perception, or space-
motion perception. DLB patients taking levodopa did not
differ in any visual score compared to those patients not
taking levodopa; such comparison was not feasible in PDD,
since all patients were taking levodopa.
Table 2 CAMCOG data
NC, n  25 PD, n  24 PDD, n  24 DLB, n  20 AD, n  23
Between-group
comparisons
Orientation (max. 10) 9.7  0.6 9.4  1.0 7.0  2.3 5.8  2.5 5.0  2.3 p  0.0001*
Attention (max. 7) 6.5  1.1 6.1  1.1 3.7  2.2 3.6  2.5 4.8  2.3 p  0.0001†
Abstract thinking (max. 8) 7.4  1.1 4.8  2.2 4.1  2.2 4.3  2.9 4.9  2.1 p  0.0001‡
Language and calculation (max. 32) 30.3  1.7 28.8  2.1 22.6  4.2 23.1  3.9 24.3  3.6 p  0.0001†
Praxis (max. 6) 5.5  0.8 5.4  0.9 4.8  1.6 4.9  0.9 5.0  0.8 NS
Visual construction (max. 6) 5.6  0.6 5.0  0.9 2.0  1.7 1.8  1.6 3.4  1.6 p  0.0001§
Perception (max. 9) 7.9  1.3 7.3  1.1 5.2  2.1 4.0  2.2 6.3  1.6 p  0.0001¶
Memory (max. 27) 23.6  1.8 23.0  2.6 16.7  4.8 14.9  4.9 9.8  4.8 p  0.0001
CAMCOG total (max. 105) 96.4  5.0 89.4  8.2 67.3  13.7 61.9  15.9 63.6  14.7 p  0.0001†
Values are mean  SD.
Post-hoc Bonferroni tests compared NC vs PD, PDD vs PD, PDD vs DLB, PDD vs AD, and DLB vs AD, and significant group differ-
ences are reported:
* PDD vs PD: p  0.0001; PDD vs AD: p  0.004.
† PDD vs PD: p  0.0001.
‡ NC vs PD: p  0.01.
§ PDD vs PD: p  0.0001; PDD vs AD: p  0.006; DLB vs AD: p  0.002.
¶ PDD vs PD: p  0.0001; DLB vs AD: p  0.0001.
 PDD vs PD: p  0.0001; PDD vs AD: p  0.001; DLB vs AD: p  0.003.
CAMCOG  Cambridge Cognitive Examination Scale; NC  normal controls; PD  non-demented Parkinson disease; PDD  Parkin-
son disease dementia; DLB  Dementia with Lewy bodies; AD  Alzheimer disease; NS  not significant (p  0.05).
Figure. (A through C) Mean and 95% CI of the discrimination score (A), of errors in object-form perception (B), and er-
rors in space-motion perception (C). There was no difference in any of these scores between the DLB and PDD groups, but
DLB and PDD tended to perform worse compared to AD patients. PDD and DLB patients made more errors in object-
form perception than in space-motion perception. NC  normal controls; PD  Parkinson disease; PDD  PD dementia;
DLB  Dementia with Lewy bodies; AD  Alzheimer disease.
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Discussion. We assessed visual perception in pa-
tients with PDD and DLB compared with AD and
two control groups—NC and nondemented PD pa-
tients. PDD and DLB had similar visuoperceptual
impairments but were more impaired compared to
patients with AD. Visual perception of PDD/DLB pa-
tients with visual hallucinations was worse than in
patients without hallucinations.
Combined retinal and cortical changes need to be
addressed to understand the extent of perceptual im-
pairment affecting all test scores. PDD and DLB are
both associated with profound cortical cholinergic
deficits and cortical Lewy body pathology in areas
involved in visual perception33,34 and functional im-
aging studies have reported hypoperfusion in the oc-
cipital and parietal lobes, occipital changes
consistently exceeding those found in AD.15,16 These
findings suggest abnormal function of visual cortical
areas. Additional retinal changes cannot be ex-
cluded, since some visual abnormalities, such as im-
paired contrast vision, are mediated by disruption of
dopaminergic processes in the retina35,36 and are un-
likely to be discovered during routine neurologic ex-
amination or by ordinary high contrast visual acuity
testing.
The dissociation between performance in object-
form and space-motion perception found in PDD and
DLB but not in AD patients may indicate a deficit in
the ventral visual pathway in these groups. This
finds support in studies reporting profound cholin-
ergic deficits and greater Lewy body density in the
temporal lobes.34,37,38 However, it is possible that the
differences observed are partly related to non-
specific visuocognitive deficits. Object-form percep-
tion tasks may be more sensitive than space-motion
perception tasks because they may contain more vi-
sual information or require more complicated solu-
tion strategies.10 The better perfusion seen on
SPECT imaging in DLB/PDD in the ventral stream
compared with the dorsal stream16 does not necessar-
ily equate with better function, since it may reflect
compensatory increase in activity in structurally al-
tered brain areas.
Visual impairments in DLB patients with visual
hallucination exceed those without hallucination, es-
pecially in the overlapping figure task39 and in the
line orientation task.40 Barnes and David41 compared
visual imagery, visual perception, and recognition
memory in nondemented PD patients with and with-
out hallucinations and found that PD patients with
visual hallucinations were more impaired in object
perception. In the present study, hallucinating DLB/
PDD patients were more impaired in all visual
scores compared to patients without hallucinations.
The interpretation of this finding needs caution, be-
cause as in previous studies,39,40 the number of de-
mented patients without hallucinations in this study
was small (n  8).
The neuropsychological (CAMCOG) data confirm
previous findings showing that visuoconstructional
abilities are more impaired in PDD and DLB com-
pared to AD and that memory function is relatively
preserved.11,42,43 In contrast to most previous studies,
which reported additional frontal impairment in
PDD and DLB, we did not find differences in the
attentional scores. The numerical tasks used to as-
sess attention in the CAMCOG battery may be in-
sensitive to detect group differences within
demented patients. One study44 which compared the
cognitive profile of AD and DLB patients using the
CAMCOG battery also did not find attentional differ-
ences. Since CAMCOG visual construction scores in
DLB also correlated with the severity of extrapyra-
midal motor symptoms, it is likely that some of the
visual constructional impairment is related to motor
impairment in the DLB group. This underpins the
need for tasks that are independent of motor func-
tion when testing visual perception in patients with
combined extrapyramidal and cognitive impairment.
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Table 3 Comparison of DLB/PDD patients with and without recurrent visual hallucinations (RVH)
DLB/PDD without
RVH, n  8
DLB/PDD with
RVH, n  36 Statistics
Age, y 78.5  8.5 75.8  6.1 NS
Education, y 14.0  1.9 13.6  1.7 NS
MMSE (max. 30) 21.8  4.2 19.8  4.5 NS
Parkinsonism, % 100 92 NS
Fluctuation, % 38 47 NS
Discrimination, z-values 0.09  0.6 0.65  0.88 p  0.030
Errors object-form perception, % 22.1  19.5 39.8  19.6 p  0.031
Errors space-motion perception, % 6.5  5.5 17.6  13.4 p  0.028
Values are mean  SD.
DLB  Dementia with Lewy bodies; PDD  Parkinson disease dementia; NS  not significant (p  0.05); MMSE  Mini-Mental State
Examination.
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